CDK4 and breast cancer: Later, Fusco V et al. [34] published a comment indicating that the study by Marcianò et al. lacked consistency because it described six cases of MRONJ in patients with breast cancer treated with osteoclast inhibitors and CDK4/6 inhibitors among a total of sixteen cases of MRONJ in patients at a reference centre for oral care.